Core Insights - Royalty Pharma plc has appointed Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, enhancing its leadership team with expertise in biopharmaceuticals and finance [1][2][3] Group 1: Board Appointments - Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, with 20 years of experience in biopharma, previously serving as Vice President of Clinical Development at Genentech [2][3] - Bess Weatherman has 35 years of experience as an investor in the healthcare industry and is currently a Special Limited Partner at Warburg Pincus, having joined the firm in 1988 [3] Group 2: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector, collaborating with various innovators [4] - The company has a portfolio that includes royalties on over 35 commercial products and 16 development-stage product candidates, indicating a strong position in the market [4] Group 3: Corporate Governance - The appointment of the new board members increases independent representation on the board to over 90%, reflecting Royalty Pharma's commitment to enhanced corporate governance [5]

Core Insights - Royalty Pharma will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 [1] - The event will be accessible via a webcast on Royalty Pharma's website and archived for at least thirty days [1] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector [2] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, to support innovation [2] - Royalty Pharma's portfolio includes royalties from over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 15 development-stage product candidates [2]

Group 1 - Royalty Pharma appointed Vlad Coric, M.D. to its Board of Directors, effective immediately [1][2] - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company with a focus on neuroscience, immunology, and oncology [1][2] - Coric's leadership at Biohaven included the FDA approval and launch of Nurtec ODT for migraine treatment and the filing of an NDA for zavegepant [2][3] - Under Coric's leadership, Biohaven grew significantly and was sold to Pfizer for approximately $13 billion in May 2022 [2] Group 2 - Coric has over 20 years of experience in drug discovery and clinical development, with expertise in various therapeutic areas [3] - His educational background includes a medical degree from Wake Forest University and a Bachelor of Science degree from the University of Connecticut [3] - Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry [4] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties on over 35 commercial products [4]

Core Insights - Royalty Pharma plc has appointed Vlad Coric, M.D. to its Board of Directors, effective immediately, enhancing its leadership team with his extensive biopharmaceutical experience [1][2]. Group 1: Appointment and Leadership - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company focused on neuroscience, immunology, and oncology [1][2]. - Pablo Legorreta, CEO of Royalty Pharma, expressed excitement about Coric's appointment, highlighting his entrepreneurial approach and leadership skills as valuable assets [2]. - Coric has notable experience in royalty funding, having completed multiple transactions with Royalty Pharma during his time at Biohaven [2]. Group 2: Achievements and Experience - Under Coric's leadership, Biohaven achieved FDA approval and launched Nurtec ODT for migraine treatment, and filed an NDA for zavegepant, the first intranasal CGRP antagonist for ultra-rapid migraine relief [2]. - Coric oversaw Biohaven's growth from its founding to its sale to Pfizer in May 2022 for approximately $13 billion [2]. - He has over 20 years of experience in drug discovery and clinical development, with expertise across various therapeutic areas including neurology, psychiatry, and oncology [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [4]. - The company collaborates with a range of innovators, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties based on top-line sales of leading therapies [4]. - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 15 development-stage candidates, indicating a strong position in the biopharmaceutical market [4].